Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
10.27
-0.52 (-4.82%)
At close: Aug 28, 2026, 4:00 PM EDT
10.50
+0.23 (2.24%)
After-hours: Aug 28, 2026, 7:48 PM EDT
Olema Pharmaceuticals Employees
Olema Pharmaceuticals had 150 employees as of June 30, 2026. The number of employees increased by 33 or 28.21% compared to the same quarter last year.
Employees
150
Change
33
Growth
28.21%
Revenue / Employee
n/a
Profits / Employee
-$1,363,780
Market Cap
898.60M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 150 | 33 | 28.21% | 150 | 0 |
| Mar 31, 2026 | 137 | 35 | 34.31% | 137 | 0 |
| Dec 31, 2025 | 131 | 35 | 36.46% | 131 | 0 |
| Sep 30, 2025 | 122 | 34 | 38.64% | 122 | 0 |
| Jun 30, 2025 | 117 | 28 | 31.46% | 116 | 1 |
| Mar 31, 2025 | 102 | 26 | 34.21% | 101 | 1 |
| Dec 31, 2024 | 96 | 22 | 29.73% | 96 | 0 |
| Sep 30, 2024 | 88 | 18 | 25.71% | 87 | 1 |
| Jun 30, 2024 | 89 | 17 | 23.61% | 80 | 9 |
| Mar 31, 2024 | 76 | 13 | 20.63% | 75 | 1 |
| Dec 31, 2023 | 74 | -12 | -13.95% | 74 | 0 |
| Sep 30, 2023 | 70 | -5 | -6.67% | 70 | 0 |
| Jun 30, 2023 | 72 | -3 | -4.00% | 67 | 5 |
| Mar 31, 2023 | 63 | -8 | -11.27% | 62 | 1 |
| Dec 31, 2022 | 86 | 12 | 16.22% | 83 | 3 |
| Sep 30, 2022 | 75 | 14 | 22.95% | 73 | 2 |
| Jun 30, 2022 | 75 | 24 | 47.06% | 72 | 3 |
| Mar 31, 2022 | 71 | 34 | 91.89% | 70 | 1 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Wave Life Sciences | 317 |
| Geron | 258 |
| Adlai Nortye Group | 109 |
| Cybin | 100 |
| Annexon | 92 |
| Theravance Biopharma | 90 |
| SpyGlass Pharma | 76 |
OLMA News
- 13 days ago - Olema Oncology price target lowered to $46 from $52 at JPMorgan - TheFly
- 13 days ago - Olema Oncology appoints Jason O’Byrne as CFO - TheFly
- 19 days ago - Olema Oncology price target lowered to $20 from $23 at Goldman Sachs - TheFly
- 19 days ago - Olema Oncology price target lowered to $59 from $62 at Citi - TheFly
- 19 days ago - Olema Oncology price target lowered to $36 from $38 at H.C. Wainwright - TheFly
- 20 days ago - Olema Pharmaceuticals Earnings release: Q2 2026 - Filings
- 20 days ago - Olema Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 25 days ago - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire